title: Involvement of aspartic and glutamic residues in kringle-2 of tissue-type plasminogen activator in lysine binding, fibrin binding and stimulation of activity as revealed by chemical modification and oligonucleotide-directed mutagenesis.
abstract: Modification of glutamic and aspartic acid residues of tissue-type plasminogen activator (t-PA) with 1-ethyl-3(3-dimethyl-aminopropyl)-carbodiimide leads to a decrease in affinity for lysine and fibrin, to a decrease of plasminogen activation activity in the presence of a fibrin mimic, but leaves amidolytic activity and plasminogen activation without fibrin mimic unaffected. Experiments with kringle-2 ligands and a deletion mutant of t-PA (K2P) suggests that glutamic or aspartic acid residues in K2 of t-PA are involved in stimulation of activity, lysine binding and fibrin binding. Mutant t-PA molecules were constructed by site-directed mutagenesis in which one or two of the five aspartic or glutamic acid residues in K2 were changed to asparagine or glutamine respectively. Mutation of Asp236 and/or Asp238 leads to t-PA molecules with 3- to 4-fold lower specific activity in the presence of fibrin mimic and having no detectable affinity for lysine analogs. However, fibrin binding was not influenced. Mutation of Glu254 also leads to a 3- to 4-fold lower activity, but to a much smaller reduction of lysine or fibrin binding. Residues Asp236 and Asp238 are both essential for binding to lysine derivatives, while Glu254 might be involved but is not essential. Residues Asp236, Asp238 and Glu254 are all three involved in stimulation of activity. Remarkably, mutation of residues Asp236 and/or Asp238 appears not to influence fibrin binding of t-PA whereas that of Glu254 does.
authors.affiliation: Gaubius Institute TNO, Leiden, The Netherlands.
authors.forename: E J
authors.initials: EJ
authors.lastname: Weening-Verhoeff
authors.forename: P H
authors.initials: PH
authors.lastname: Quax
authors.forename: R T
authors.initials: RT
authors.lastname: van Leeuwen
authors.forename: E F
authors.initials: EF
authors.lastname: Rehberg
authors.forename: K R
authors.initials: KR
authors.lastname: Marotti
authors.forename: J H
authors.initials: JH
authors.lastname: Verheijen
mesh_terms: D000595:Amino Acid Sequence; D001224:Aspartic Acid / Q000378:metabolism*; D001483:Base Sequence; D005022:Ethyldimethylaminopropyl Carbodiimide / Q000494:pharmacology; D005337:Fibrin / Q000378:metabolism; D005971:Glutamates / Q000378:metabolism*; D007700:Kinetics; D008239:Lysine / Q000378:metabolism; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D010446:Peptide Fragments / Q000378:metabolism*; D010958:Plasminogen / Q000378:metabolism*; D015202:Protein Engineering; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000378:metabolism*
chemical_list: D005971:Glutamates; D010446:Peptide Fragments; D001224:Aspartic Acid; D005337:Fibrin; D010958:Plasminogen; D010959:Tissue Plasminogen Activator; D008239:Lysine; D005022:Ethyldimethylaminopropyl Carbodiimide